SEC Company Response from PEREGRINE PHARMACEUTICALS INC (CDMO) (CIK 0000704562) — Sep 28, 2005

PEREGRINE PHARMACEUTICALS INC (CDMO) (CIK 0000704562)
Date: Sept. 28, 2005 · CIK: 0000704562 · Accession: 0001019687-05-002700

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-128322

Date

Sept. 28, 2005

Author

PEREGRINE

Form

CORRESP

Company

PEREGRINE PHARMACEUTICALS INC (CDMO) (CIK 0000704562)

Letter

Division of Corporate Finance Securities and Exchange Commission Attn: Mr. Jeffrey P. Riedler - Assistant Director RE: Peregrine Pharmaceuticals, Inc. Registration Statement on Form S-3 (333-128322)

Dear Mr. Riedler:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), the undersigned hereby requests that the effective date of the above referenced Registration Statement be accelerated so that the Registration Statement may become effective at 9:00 a.m., eastern standard time, on Thursday, September 29, 2005, or as soon thereafter as practicable. By making this request for acceleration, the undersigned hereby acknowledges and accepts its responsibilities under the Act.

In this regard, the undersigned acknowledges that:

1. Should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

2. The action of the Commissioner or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its responsibility for the adequacy and accuracy of the disclosure in the filing; and

3. The Registrant may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States

Very
truly yours,
PEREGRINE
PHARMACEUTICALS, INC.

Show Raw Text

CORRESP
1
filename1.htm

      Peregrine Acceleration request

    [PEREGRINE
      PHARMACEUTICALS, INC.  LETTERHEAD]

    September
      28, 2005

    Sent
      Via Fax to (202) 772-9217 and Federal Express

    Division
      of Corporate Finance

    Securities
      and Exchange Commission

    450
      Fifth
      Street, N.W.

    Washington
      D.C. 20549

    Mail
      Stop
      0309

    Attn:
      Mr.
      Jeffrey P. Riedler - Assistant Director

              RE:

              Peregrine
                Pharmaceuticals, Inc.

              Registration
                Statement on Form S-3
                (333-128322)

    Dear
      Mr.
      Riedler:

    Pursuant
      to Rule 461 under the Securities Act of 1933, as amended (the “Act”), the
      undersigned hereby requests that the effective date of the above referenced
      Registration Statement be accelerated so that the Registration Statement may
      become effective at 9:00 a.m., eastern standard time, on Thursday, September
      29,
      2005, or as soon thereafter as practicable. By making this request for
      acceleration, the undersigned hereby acknowledges and accepts its
      responsibilities under the Act.

    In
      this
      regard, the undersigned acknowledges that:

    1.     Should
      the Commission or the staff, acting pursuant to delegated authority, declare
      the
      filing effective, it does not foreclose the Commission from taking any action
      with respect to the filing;

    2.     The
      action of the Commissioner or the staff, acting pursuant to delegated authority,
      in declaring the filing effective, does not relieve the Registrant from its
      responsibility for the adequacy and accuracy of the disclosure in the filing;
      and

    3.     The
      Registrant may not assert this action as defense in any proceeding initiated
      by
      the Commission or any person under the federal securities laws of the United
      States

              Very
                truly yours,

              PEREGRINE
                PHARMACEUTICALS, INC.

              /s/
                STEVEN W. KING

              Steven
                W. King

              President
                and Chief Executive Officer

SecProbe.io